Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study

Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case–Control Study

(2013) Fei-Yuan Hsiao et al.   DRUG SAFETY

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

(2013) Andre Scheen   Expert Opinion On Drug Safety

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds

(2013) D. Cohen   BMJ-British Medical Journal

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

Increased risk of severe acute pancreatitis in patients with diabetes

(2012) H.-N. Shen et al.   DIABETIC MEDICINE

A systematic review of validated methods for identifying pancreatitis using administrative data

(2012) Kevin Moores et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Risk of Acute Pancreatitis in Type 2 Diabetes and Risk Reduction on Anti-Diabetic Drugs: A Population-Based Cohort Study in Taiwan

(2011) Shih-Wei Lai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic Drugs: A population-based cohort study

(2010) A. Gonzalez-Perez et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

(2010) C. J. Girman et al.   DIABETES OBESITY & METABOLISM

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

(2010) R. Garg et al.   DIABETIC MEDICINE

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

(2010) S. S. Engel et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Incidence, Resource Use, and Outcome of Acute Pancreatitis With/Without Intensive Care

(2010) Hsiu-Nien Shen et al.   PANCREAS

The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan

(2010) Yu-Wen Wen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan

(2010) Fei-Yuan Hsiao et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study

(2009) F.-Y. Hsiao et al.   DIABETOLOGIA

Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

(2009) Fei-Yuan Hsiao et al.   DRUG SAFETY

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

(2008) Debora Williams-Herman et al.   BMC Endocrine Disorders